US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.01 against a street estimate of -0.01 — a beat of 200.0%.
Analysts rate Xeris Pharmaceuticals Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $11.29.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.50% |
| D. E. Shaw & Co LP | 4.51% |
| Vanguard Capital Management, LLC | 4.04% |
| State Street Corp | 2.70% |
| Geode Capital Management, LLC | 2.49% |
| Qube Research & Technologies | 2.38% |
| Rosalind Advisors, Inc. | 1.87% |
| Nuveen, LLC | 1.69% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-17 |
| Board / officer change · Q2 2026 | 2026-06-30 |
| Company announcement · Q2 2026 | 2026-06-11 |
| Shareholder vote results · Q2 2026 | 2026-06-05 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q4 2025 | 2026-04-23 |
| Annual report FY2025 | 2026-03-02 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Xeris Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.